|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
QCIP |
Brustkrebs
|
Multizentrische, nicht-interventionelle, prospektive Beobachtungsstudie zur Untersuchung der Wirksamkeit und Verträglichkeit der lokalen Behandlung von Chemotherapie-induzierter Polyneuropathie (CIPN) mit QUTENZA® bei Mammakarzinom-Patientinnen
|
 |
 |
|
|
Pyrenees 1517-CL-0613 |
Sonstige Studien
-
|
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis Converted from Epoetin or Darbepoetin Alfa Treatment
|
|
|
|
|
PYR311-PIONEER |
Glomeruläre Krankheiten bei Diabetes mellitus
[N08.3*]
|
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin in Subjects with Nephropathy Due to Type 2 Diabetes.
|
|
|
|
|
Protocol SAKK 09/10 |
Prostatakrebs
|
Dose intensified salvage radiotherapy in biochemically relapsed prostate cancer without macroscopic disease. A randomized phase III trial.
|
|
|
|
|
Prostata Biomarker Studie |
Prostatakrebs
|
Identifikation von Biomarkern zur Prädiktion der biochemischen Kontrolle (bNED) nach Salvage Strahlentherapie des Prostatakarzinoms
|
 |
|
|
|
PROOF |
Bauchspeicheldrüsenkrebs (Pankreas)
|
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
|
|
|
|
|
PROBASE |
Prostatakrebs
|
Risk-adapted prostate cancer (PCa) early detection study based on a “baseline” PSA value in young men – a prospective multicenter randomized trial
|
|
|
|
|
Pro pocket (Tiloop) |
Brustkrebs
|
International, prospective, multicentre post-market surveillance study "Patient Reported Outcome" in primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh (TiLOOP® Bra Pocket)
|
|
|
|
|
PRO B |
Brustkrebs
|
– Patient Reported Outcomes bei Brusterkrankungen Neue Wege in der Versorgung bei metastasiertem Brustkrebs
|
|
|
|
|
PREFER |
Speiseröhrenkrebs
|
Endoscopic management of patients with high risk T1a or T1b N0M0 esophageal adenocarcinoma -a prospective multicenter registry -
|
|
|
|
|
PRAEGNANT |
Brustkrebs
|
Prospektives akademisches translationales Forschungsnetzwerk zur Optimierung der onkologischen Versorgungsqualität in der adjuvanten und fortgeschrittenen /metastasierten Situation: Versorgungsforschung, Pharmakogenetik, Biomarker, Pharmakoökonomie
|
|
|
|
|
PONIY |
Tumor des Dickdarms / Mastdarms
Tumor des Dickdarms / Mastdarms
|
Postoperative Inzisions-Unterdrucktherapie nach offenen kolorektalen Eingriffen: eine randomisiert-kontrollierte Studie (Poniy)
|
|
|
|
|
POLO Olaparib |
Bauchspeicheldrüsenkrebs (Pankreas)
|
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
|
|
|
|
|
POLESTAR |
Sonstige Tumore
|
Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and OLaparib as firstline therapy in Her-2 negative gastric/gastroESophageal-juncTion (GEJ) AdenocaRcinoma
|
|
|
|
|
POLE-1 |
|
Pembrolizumab in MarginalzoneLymphoma - A multicenter open Label single-arm Phase II study
|
|
|
|
|
PNET 5 MB |
ZNS Tumore
|
Keine Angabe
|
|
|
|
|
PLATIN – ARO 2009-05 |
Prostatakrebs
|
Prostata- und Lymphabflussbestrahlung mit integrierter-boost-IMRT nach neoadjuvanter Hormontherapie
|
|
|
|
|
PINIT |
Diabetes mellitus, Typ 1
[E10.-]
|
PINIT Study: An immune efficacy study for primary prevention using intranasal insulin therapy
in islet autoantibody negative children at high genetic risk for type 1 diabetes
|
|
|
|
|
PHI113633 |
Sonstige Studien
-
|
A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response ralationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24weeks in hemodialysis-dependent subjects with anemia asociated with chronic kidney disease who switch from recombinant human erythropoietin.
|
|
|
|
|
PHERGain_MedOPP096 |
Brustkrebs
|
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer:
FDG-PET response-adapted strategy. The PHERGain study
|
|
|
|
|
PH-L19TNFDOX2-03/16 |
Sarkome (Knochen- und Weichteilkrebs)
C40-C41
|
A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma Z-Nr.: 416
|
|
|
|
|
Pfizer Studie A3921080 |
Psoriasis, nicht näher bezeichnet
[L40.9]
|
Keine Angabe
|
|
|
|
|
PET-Plan NSCLC; AG NUK/RT 2006-1 |
Lungenkrebs
Lungenkrebs
Lungenkrebs
Lungenkrebs
Lungenkrebs
Lungenkrebs
|
Optimierung der Strahlentherapieplanung von Patienten mit inoperablen lokal fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoen mittels F-18-FDG. Prospektive randomisierte multizentrische Therapieoptimierunsgsstudie
|
|
|
|
|
Perikardprothesenregister |
Aortenaneurysma nicht näher bezeichneter Lokalisation, ohne Angabe einer Ruptur
[I71.9]
|
Ersatz von infizierten Aorten und Aortengrafts mit selbstgemachten bovinen Perikardprothesen: eine europäische multizentrische Studie
|
|
|
|
|
PERCOG |
Magentumor
Magentumor
|
Parenterale Ernährung unter neoadjuvanter Chemotherapie beim lokal fortgeschrittenen Magenkarzinom/Karzinom des ösophagogastralen Übergangs zur Reduktion der postoperativen Morbidität
|
|
|
